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Lymphocyte apoptosis in the pathogenesis of type 1 diabetes mellitus  
 
INTRODUCTION 
Type 1 diabetes mellitus (DM1) is the effect of T 
cell dependant autoimmune destruction of insulin 
producing beta cells in the pancreatic islets. T cells 
are activated in response to islet dominant 
autoantigens, the result being the development of 
type 1 diabetes mellitus.1 
Apoptosis (a combination of the Greek word apo: 
off/ and Potosi: falling) is a highly regulated form 
of cell death defined by distinct morphological and 
biochemical features.2 It is a coordinated series of 
events for the programmed cell death, and plays an 
important role in the maintenance of tissue 
homeostasis, embryonic development, and in the 
control of immune responses in humans.3 
Fas (Apo-1/ CD95) is a 45-KDa surface receptor 
belonging to the nerve growth factor superfamily, 
which on binding by Fas ligand (FasL) induces 
translocation of phosphatidylserine from the inner 
to the outer leaflet of the cellular membrane and 
directly transduces the signal for programmed cell 
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death (apoptosis).4 Mature T lymphocytes express 
Fas (CD95/Apo1) molecules. Their expression can 
be enhanced upon activation of the T cell by 
autoantigen or inflammation and these cells become 
more sensitive to FasL mediated apoptosis3. 
Defective regulation of leukocyte apoptosis may be 
a factor which contributes to the pathogenic 
mechanism of autoimmune diseases.5 It was found 
that immunological, inflammatory and metabolic 
signals cause β-cell apoptosis, and that these signals 




This study comprised 90 children and adolescents, 
who were divided into three groups.  
Group (1): It comprised 40 type-1 diabetic children 
and adolescents recruited from the regular 
attendants of the Pediatric Diabetes Clinic, 
Children's Hospital, Ain Shams University.  
Inclusion criteria: 
a) Disease duration > 1 year 
b) Regular insulin therapy 
They were 17 males and 23 females. Their ages 
ranged from 8.0 to 17.0 years with a mean of 
12.96+2.55 years. Their disease duration ranged 
between 2.0 and 12.0 years with a mean of 
4.90+2.55 years. All the patients included were 
under human insulin therapy in a dose ranging from 
1.1-3.0 U/Kg/day with a mean of 1.765+0.667 
U/Kg/day. Twenty six were non-complicated and 
14 had chronic microvascular complications.  
Group (2): It comprised 30 euglycaemic 
prediabetic children and adolescents.  
Inclusion criteria: 
a. First degree relatives of type 1diabetic patients. 
b. No clinical signs of the disease. 
c. Normal fasting blood glucose level. 
d. Positive First Phase Insulin Release (FPIR) and/or 
positive ICA or GAD antibodies. 
They were 14 males and 16 females. Their ages 
ranged from 9.0 to 17.0 years with a mean of 12.90 
+2.48 years.  
Group (3): This group comprised 20 healthy age 
and sex matched children and adolescents who 
served as a control group.  
Inclusion criteria: 
a- No clinical or laboratory signs of type-1 diabetes. 
b- No family history of diabetes in their first or 
second degree relatives.  
They were 9 males and 11 females. Their ages 
ranged from 9.0 to 17.0 years with a mean of 
13.50+2.48 years.  
 
 
All patients were subjected to the following: 
A. History taking through a structured questionnaire 
planned to fulfill the following data: Demographic 
data, disease duration, insulin therapy (type, dose 
and frequency), history suggestive of acute 
metabolic complications and history suggestive of 
chronic diabetic complications. Their files were 
revised for the presence of hypertension, 
microalbuminuria and diabetic retinopathy. 
B. Physical examination with particular emphasis 
on: 
1- Anthropometric measurements: The weight 
(Kg) and height (cm) values were plotted against 
percentiles for age and sex according to Egyptian 
growth charts. The body mass index was 
calculated. 
2- Assessment of sexual maturity according to the 
Tanner's classification.  
3- Neurological examination for evidence of 
peripheral neuropathy. 
4- Fundus examination using direct ophthalmo-
scopy to detect diabetic retinopathy. 
C. Laboratory investigations: 
Fasting blood glucose was measured for all 
prediabetics and controls to exclude the possibility 
of being diabetics. The sibs were followed up 
throughout the study for the development of DM. 
a. Random blood sugar (RBS): performed on CX9 
system (Beckman Corporation Brea, California, 
USA).  
b. Glycosylated hemoglobin (HbA1c): using 
quantitative calorimetric determination of 
glycohemoglobin in whole blood by Teco 
Diagnostics 1268 N. LAKEVIEW AVE USA–
ANAHEIM, CA 92807, 1-800-222-9880. It was 
measured as a reflection of long term glycemic 
control over the preceding 12 weeks. 
c. Quantitative determination of urinary 
microalbumin as a predictor of diabetic 
nephropathy. Microalbuminuria was defined as 
excretion rate of albumin 30-300 mg/gm urinary 
creatinine. Calculation of mean random blood 
sugar, mean HbA1c in the last year prior to the 
study was done retrospectively from the patients' 
files. 
d. Flow cytometric assessment of CD3 lymphocytes 
and CD95 percentage expression on peripheral 
lymphocytes as a measure of apoptosis. 
Evaluation of the surface expression of CD3 and 
CD95 T cell subsets on gated lymphocytes was 
performed by flowcytometry (Coulter electronics 
EPICS-XL, FT, USA). Two ml of venous blood 
were drawn from each patient into a tube 
containing K-EDTA solution. Monoclonal 
antibodies were used included CD3 [fluorescene 
Lymphocyte apoptosis in type 1 DM 
59 
isothiocyanate (FITC) labeled, CD95 
(phycoerythrin (PE) labeled] (coulter). Isotypic 
negative controls FITC, PE, labeled were used to 
determine the non specific binding (coulter), and 
Lysing solution (NH4Cl buffered with KHCO3 at 
PH 7.2). 
For each sample, one assay and one control tube 
were used 50 μL whole blood were  delivered in 
each tube, monoclonal antibodies and isotypic 
controls were added in the test tube and control 
tube respectively. The tubes were vortexed and 
incubated for 15 minute at room temperature in 
the dark cells were then washed in P.B.S. Stained 
samples were then treated with lysing solution, 
then incubated for 37oC and washed again prior to 
flow cytometric analysis. Analysis of the results 
was done on flow cytometer (coulter electronics 
Epics-XL, FT, USA) equipped with 480 nm air-
cooled Argon Laser.  The data was plotted on 3 
histograms. The first histogram was based on 
forward scatter (FS) versus side scatter (SS) 
where lymphocytes are gated. The second 
histogram measures the percentage expression of 
CD3. The third histogram measures the 
percentage of CD95 expression as mean 
florescence intensity or percentage of gated 
positive cells for antibody used. 
e. Glutamic acid decarboxylase autoantibodies: 
These were measured by radiological based assay 
(CentAKr anti-GAD65, Medpan Diagnostica, 
Entwicklungs-undvertriebs GmbH. Germany) for 
the prediabetics and controls. A cut off values of 
antibody positivity were determined using mean 
values of controls + 2SD.  
f. Islet-cell autoantibodies (ICA): They were 
assessed using the indirect immuno-fluorescence 
(IIF) technique, (Medica/ APICA kit) for the 
prediabetics and controls.  
g. First Phase Insulin Release (FPIR): This was 
performed for prediabetics who had one positive 
antibody assay and controls. 
A solution of 25% dextrose (0.5 g/kg body weight 
up to a maximum of 35g) was infused over 3 
minutes±15 seconds. Blood samples for 
determination of glucose and insulin level were 
drawn at 1, and 3 minutes after the end of glucose 
infusion. The insulin values at 1 and 3 minutes after 
the end of glucose infusion were added to 
determine the first phase insulin release which is 
termed (FPIR). Enzyme Amplified Sensitivity 
Immunoassay method was used on microtiter plate 
MEDGENI INS-ESIA. Several monoclonal 
antibodies (mabs) directed against specific epitopes 
of insulin are used, which allow highly sensitive 
assays and avoid hyperspecificity. Standard or 
samples containing insulin INS react with capture 
antibodies (mabs1) coated on a plastic wells and 
with a second monoclonal antibodies labeled with 
horseradish peroxidase (HRP) (conjugate) An 
incubation period is given to allow the formation of 
a sandwich: coated (mabs1) - INS- (mabs2) in HRP. 
Washing step was done to remove unbound enzyme 
labeled antibodies. A substrate was added 
tetramethylbenzydine (TMB H2O2) was added then 
followed by a second incubation period. Optical 
density (OD) of the studied samples and standards 
were read using the specific wave length. A 
standard curve was plotted using standards 
concentrations and OD readings. Insulin 
concentrations in samples were determined by 
interpolation from the curve. According to Chase et 
al.7 FPIR was classified with modification into low 
risk group (>80-100mu/L), intermediate risk group 
(65-80mu/L) and high risk group (<65-48mu/L) 
less than 5th percentile and (<48mu/L) less than first 
percentile.   
 
Statistical analysis: 
Standard computer program SPSS for Windows, 
release 10.0 (SPSS Inc, USA) was used for data 
entry and analysis. All numeric variables were 
expressed as mean ± standard deviation (SD). 
Comparison of different variables in various groups 
was done using Mann Whitney test for 
nonparametric variables. Chi-square (χ2) test was 
used to compare frequency of qualitative variables 
among the different groups. Spearman’s correlation 
test was used for correlating the non-parametric 
variables. For all tests a probability (p) less than 
0.05 was considered significant.  
 
RESULTS 
Table (1) summarizes the demographic and clinical 
data of the studied sample. The studied groups were 
comparable in terms of sex and age distribution 
although a higher percentage of positive 
consanguinity and positive family history of type-1 
DM were found in the diabetics and prediabetics 
compared to controls (P <0.05). Non-significant 
differences in weight, height and BMI were found 
between the studied groups. Although the mean 
weight and height percentiles were lower in type-1 
diabetic patients, the difference did not reach a 
statistical significance.  No significant difference 
could be elicited between the studied groups in 
puberty staging. Higher mean heart rate, systolic 
and diastolic blood pressure values were found in 
diabetics when compared to prediabetics and 
controls although statistically non significant. 
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Table (2) shows the metabolic parameters and 
complications of the studied diabetic patients. Forty 
diabetic patients were included with a mean disease 
duration of 4.90±2.55 years. Their mean RBS was 
248.38±39.4 mg/dL, mean HbA1c was 8.58±1.18% 
and their mean insulin dose was 1.76±0.66 u/kg/day. 
The frequencies of occurrence of chronic 
microvascular complications were as follows; 15% 
had nephropathy, 12% had neuropathy and 7.5% had 
diabetic retinopathy. Regarding the acute diabetic 
complications, 5% had history of DKA, 13% 
experienced attacks of minor hypoglycemia and 7% 
had major hypoglycemia in the last year prior to the 
study. 
When we compared complicated and non 
complicated diabetic patients in terms of the metabolic 
and laboratory parameters; we found highly 
significant increase in disease duration, mean RBS 
and mean insulin dose in complicated compared to 
non-complicated cases (P <0.001). Also, a significant 
increase in the mean HbA1c was detected in 
complicated compared to non-complicated diabetics 
(p<0.05). Both complicated and non-complicated 
type-1 diabetic patients were comparable regarding 
their percentage of CD3 lymphocytes but a significant 
increase in CD 95% expression were found in 
complicated diabetics (Table 3). 
Thirty sibs of patients with type I DM were 
included in this study. They were derived from 38 
families. Eighteen (60%) of them (prediabetics) 
were positive for GAD65 antibodies, 26.7% were 
positive for ICA antibodies and 13.3% were 
positive for both antibodies (ICA, GAD) (table 4). 
The cut off values for antibodies positivity were 
determined using the mean value of the controls + 2 
SD. Comparison between mean level of GAD65 
Abs among prediabetics and controls revealed a 
higher level of GAD Abs in prediabetics (2.15±3.83 
U/ml) compared to controls (0.497±0.526 U/ml, 
p<0.05). Prediabetics with positivity for one 
antibody (either ICA or GAD) were subjected to 
FPIR. There was a highly significant decrease in the 
mean level of FPIR in prediabetics compared to 
controls (table 5). Grading of decreased levels of 
FPIR among the studied prediabetics was presented 
in table (6).  
The percentage of CD3 lymphocytes was 
significantly decreased in prediabetics compared to 
type-1 diabetics and controls (52.9±11.6, 
66.2±7.04, 63.9±3.4%; P <0.001). Also, there was a 
highly significant increase in CD95 molecule 
percentage expression in peripheral blood T and B 
lymphocytes in prediabetics as compared to the 
type-1 diabetics and controls (57.68±6.6, 45.0±6.6, 
16.7±4.9% respectively; P < 0.001), figure (1). 
 
 
Table 1. Demographic and clinical data of the studied groups (one-way ANOVA test) 
Variable Diabetics (n=40) 
Prediabetics
(n=30) 
















Positive consanguinity n (%) 24 (65) 20 (66.7) 4 (20) < 0.05 
Family history of type I DM n (%) 22 (55) 30 (100) 0.0 (0) < 0.05 
Sex M/F  17/23 14/16 9/11 > 0.05 
Weight percentile (mean ± SD) 37.12±28.9 39.44±29.78 39.63±36.77 > 0.05 
Height percentile (mean ± SD) 25.11±27.28 27.75±24.56 27.15±56 > 0.05 
BMI percentile (mean ± SD)  40.36±28.15 42.59±41.35 42.31±73.61 > 0.05 
Puberty  
o Normal  
o Delayed  
















Basal heart Rate (b/m)  
(mean ± SD) 86.4±13.3 86.3±9.5 82±71 > 0.05 
Systolic blood pressure 
(mean ± SD) 106±13.2 102±11.8 97.3±8.85 > 0.05 
Diastolic blood pressure   
(mean ± SD) 72±1008 67±12.2 64.6±12.2 > 0.05 
M: Male;  F: Female; BMI: Body mass index; SD: Standard deviation; b/m: beat/minute 
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Table 2. Metabolic parameters, chronic microvascular and acute 
complications of the studied type 1 diabetes patients  
 
Variable Type 1 diabetic patients  (n = 40) 
Disease duration (yr)  
Range 




Mean RBS (mg/dl)  
Range  




Mean insulin dose (U/K/d) 
Range  




Mean HbA1c (%) 
Range  




Chronic microvascular complications 
Nephropathy n (%) 
Neuropathy n (%) 





Acute complications  
DKA n (%) 2 (5) 
Hypoglycemia  
          minor n (%) 




RBS: Random blood sugar; HbA1c: haemoglobin A1c; SD: Standard deviation; DKA: 
Diabetic Ketoacidosis; n: Number. 
 
Table 3. Variations of disease duration, metabolic control and lymphocyte 






(mean ± SD) 
Complicated 
n=14 
(mean ± SD) 
Variable 
0.000 3.35+1.35 7.97+2.72 Disease duration (years) 
0.000 248.38+39.42 357.64+75.63 Mean RBS (mg/dl) 
0.000 1.419+.378 2.407+.612 Mean insulin dose (U/kg/day) 
0.018 7.976+.825 9.971+.841 Mean HbA1c (%) 
0.138 65.212+ 7.396* 68.143+6.140* CD3 (%) 
0.05 39.635+ 6.477 44.635+6.477 CD95 (%)** 
Mann- Whitney test was used in the analysis 
HbA1c: haemoglobin A1c ; RBS: Random blood sugar; SD: Standard deviation  
* Data presented as percent of labeled cells; ** CD95 antigen expression on peripheral blood 
lymphocytes   
 
Table 4. Distribution of GAD65 antibodies 
and ICA positivity among prediabetics 
 
Table 5. Mean levels of FPIR in prediabetics 
and controls 
 
High risk group n=30 No % 
-GAD65- Ab positive. 18 60 
-ICA positive. 8 26.7 














t      8.528  P < 0.01 
GAD: Glutamic acid Decarboxylase; ICA: Islet cell 
antibody; Ab: Antibody    
FPIR: First phase insulin release. P <0.05 significant;  
P <0.01 highly significant 
*Prediabetics who were positive for one antibody   
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Table 6. Grading of decreased levels of FPIR among the studied prediabetic patients (n=26) 
 
Grading of decreased levels of FPIR  Number Frequency 
I. Low risk group  
 1. Preserved FPIR (>100 mU/L) 







II. Intermediate risk group  





III. High risk group  
 4. Less than 5th percentile (<65 – 48 mU/L)







Total  26 100% 













CD 3% CD 95% CD3 CD95%
 
Figure 1. Comparison between the studied groups in terms of 
their mean percentage of CD3 lymphocytes and CD95 antigen 
percentage expression on peripheral lymphocytes. (p<0.001).  
 
Table 7. Correlation between CD3 lymphocytes and CD95 antigen 
percentage expression and some other studied variables 
 
The percentage of CD 3 lymphocytes  r p 
Age (years)  0.166 0.686 (NS)  
Disease duration (yrs)  0.010 0.952 (NS) 
Random blood sugar (mg/dL)  0.037 0.819 (NS) 
Mean insulin dose (U/kg/day) 0.034 0.835 (NS) 
HbA1c (%) 0.669 0.015 (S) 
The percentage of CD 95 molecule expression  r p  
Age in (yrs)  0.112 0.493 (NS) 
Disease duration (yrs)  -0.003 0.987 (NS) 
Random blood sugar (mg/dL)  0.097 0.550 (NS) 
Mean insulin dose (U/kg/day) 0.071 0.663 (NS) 
HbA1c (%) 0.639 0.04   (S) 
NS: Non significant; S: Significant; P<0.05 Significant  
 
A significant positive correlation was found between the percentage of CD3 lymphocytes and HbA1c 
(p<0.05). Attempts to correlate it with age, RBS, insulin dose and disease duration did not reach a statistical 
significance (P>0.05). The CD95% expression on peripheral lymphocytes could not be correlated to age, 
disease duration, RBS, insulin dose (P>0.05). HbA1c was positively correlated with CD95% molecule 
expression on peripheral blood lymphocytes (P<0.05) table (7). 








Figure 2. Flow cytometric assessment of CD3 lymphocytes and analysis of CD95 antigen expression on 
lymphocytes from peripheral blood of one diabetic patient (a), one prediabetic subject (subject with high 
risk of DM1) (b) and in one of the controls (c). There was considerable increase in CD95 molecule 
expression on lymphocytes of prediabetics.   
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DISCUSSION 
Much attention has been paid to Fas/Fas L-
mediated cell death and to the possibility that the 
triggering of death receptors on β cells might be the 
conduit for β cell destruction8,9. A high proportion 
of apoptotic lymphocytes in diabetic states may 
explain the impaired immune function in poorly 
controlled diabetic patients.10,11,12 
The present data demonstrate significant 
increase in the positive consanguinity and family 
history for DM1 in the studied diabetic and 
prediabetic groups compared to the control group. 
These results are in agreement with Lambert et al.13 
who reported that human type I diabetes requires a 
genetic background of susceptibility based on 
inheritance patterns and family studies. 
There are different approaches for identification 
of individuals at risk for development of type-1 
diabetes, during the asymptomatic preclinical 
period which may last for years during which 
progressive beta cell destruction occur. These 
approaches are based on the presence of positive 
family history of type-1 diabetes, genetic, 
autoimmune or metabolic markers. These 
alternatives may also be combined in various ways 
to improve the predictive characteristics of the 
screening strategy.11,14 
Autoantibodies to various beta cell antigens 
have proved to be an early marker of ongoing-β-cell 
destruction and were used to assess the risk of 
future manifestations of clinical disease in first 
degree relatives of patients with type-1 diabetes12,15. 
Among first-degree relatives of patients with type-1 
diabetes, the risk for clinical disease can be graded 
from <5% in those with one or no antibodies to 
>90% in individuals who carry the risk of genotype 
and are positive for multiple auto-antibodies6,16. In 
the present study 60% of the first degree relatives 
(prediabetics) were positive for GAD 65 antibodies, 
26.7% were positive for ICA antibodies and 13.3% 
were positive for both. Studies in the first-degree 
relatives of patients with type-1 diabetes have 
shown conclusively that autoantibodies to islet 
antigens precede the onset and can be used to 
predict clinical disease.17 
Our study demonstrated no significant 
difference between the studied groups in terms of 
weight, height and BMI percentiles although short 
stature and under weight were more frequently 
observed in type-1 diabetics compared to 
prediabetics and controls. This might reflect the 
notion that controlled diabetes does not 
significantly affect growth17. 
We studied 40 type-1 diabetics; 14 were 
complicated (35%) and 26 were non- complicated 
(65%). A highly significant increase was found in 
disease duration and mean random blood sugar in 
complicated compared to non-complicated diabetic 
patients (p value <0.001). The DCCT18 revealed 
that diabetes duration is clearly involved in the 
causation of microvascular complications and has 
shown that the more time individuals are exposed to 
chronically elevated plasma glucose levels, the 
greater their risk of developing diabetic 
microvascular complications. In the same way, 
ADA19 reported that postprandial hyperglycemia is 
a direct and independent risk factor for 
cardiovascular disease (CVD). 
The present study demonstrated that the 
percentage of CD3 lymphocytes was significantly 
lower in patients with a high risk of DM1 
(prediabetics) compared to both type 1 diabetics 
and controls (p <0.001). This is in agreement with 
Tchórzewski et al.1 who reported that, the 
percentage of CD3 lymphocytes was decreased in 
children with a high risk for type-1 diabetes 
compared to type-1diabetics and controls; and they 
explained this finding by the decreased percentage 
of CD3 in peripheral blood of patients with a high 
risk for DM1 (prediabetics) which reflects the 
involvement of T-cells in the local immune 
reaction. Also, it was reported by Barbeau et al.20 
that apoptosis is important in removing autoreactive 
T-cells and thus prevents the occurrence of 
autoimmune disease in prediabetics because if these 
autoreactive T-cells are not efficiently eliminated, 
the progress to autoimmune type-1 DM is enhanced 
due to destruction of pancreatic islets by 
autoreactive T-cells. 
In the present study, a significant increase in 
CD95 percentage expression was found in children 
with high risk for type-1 diabetes (prediabetics) in 
comparison to type-1 diabetics and controls 
(p<0.001). In concordance, Tchórzewski et al.1 
found that there was higher CD95 percentage 
expression in 12 prediabetics and in only 2 
diabetics although the percentage expression of 
CD95 in controls was below the sensitivity of the 
assay. They also found that, the CD95 molecule 
expression was increased in all populations of 
peripheral blood T and B lymphocytes in 
prediabetics when measured immediately after 
blood collection. Expression of both the percentage 
of CD95 molecule labeled cells and CD95 mean 
fluorescence intensity was elevated. 
Mauricio and Mandrup-Poulsen21 also reported 
that a Fas (CD95) is a potential mechanism of 
pancreatic beta cell death in DM1. In the same way, 
Chowdhry et al.22 reported that emerging evidence 
has begun to unify the genetic susceptibility and 
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genes in the apoptosis signaling machine, as 
increasing numbers of apoptosis regulatory genes 
have recently been linked to the pathogenesis of 
diabetes. Sharma et al.23 reported that CD95 
receptor expression on resting lymphocytes 
obtained from prediabetics was increased in 
comparison to healthy controls and patients with 
DM1 and they found that insulin lead to decreased 
CD95 receptor expression on lymphocytes obtained 
from prediabetics. They concluded that failure of 
autoreactive T-cells apoptosis is responsible for the 
early processes of diabetogenesis and disease 
progression. It was reported that the specific 
susceptibility of T lymphocytes from children with 
high risk for DM1 to insulin induced inflammatory 
cytokine production and anti-CD95 dependent 
apoptosis supports the clinical observation that 
small doses of insulin may inhibit disease 
progression in these individuals.8 
The CD95 molecule is responsible for increased 
apoptosis of T lymphocytes after exposure to anti-
Fas antibody. This hypothetical mechanism is 
responsible for selective elimination of specific 
autoreactive T-cells but it was not confirmed in 
large clinical trials.24  Moreover, soluble Fas ligand 
is not detected in the sera of healthy individuals, but 
it was more frequent in sera of prediabetics.25 On 
the other hand, Green2 reported a reduced 
expression of the apoptosis-inducing CD95 receptor 
on T and B lymphocytes of individuals with clinical 
and preclinical type-1 diabetes, and this defective 
expression may impair the capacity of autoreactive 
lymphocytes to undergo CD95-mediated apoptosis. 
The current study revealed a significant 
increase in CD95 percentage expression in DM1 in 
comparison to controls (p <0.000). Kohler et al.4 
reported that immunological, inflammatory, and 
metabolic signals leading to β-cell apoptosis were 
increased in diabetic patients, and they proposed 
that these signals converge toward a common β-cell 
death signaling pathway. 
The increased generation of free radicals in the 
hyperglycemic state may lead to the production of 
advanced glycation end products and the 
peroxidation reaction in lipids and protein. 
Moreover DNA is also vulnerable to the action of 
free radicals. Thus, chronic hyperglycemia at the 
onset of diabetes may be associated with increased 
genotoxicity and apoptosis, thus has an impact on 
DNA repair  machinery26,27. 
The expression of dominant-negative 
Fas(CD95) or neutralizing antibodies to Fas 
(CD95)L significantly blocks apoptosis, maintain 
adequate beta cell function, blocks transfer of 
diabetes by primed T cells, and retards the course of 
diabetes development.28 This is also supported by 
Su et al.11 who found that; apoptosis is highest in 
recent-onset type-1 diabetic subjects followed by 
high risk subjects. It was found that apoptosis 
reaching the highest level in subjects at the onset of 
the disease staying high during the period 
immediately following diagnosis, including the 
period in which the requirements for exogenous 
insulin drop dramatically and beta cell function 
improves "honey moon phase". Later on, when the 
autoimmune destruction is complete and insulin 
requirements increase, T-cell apoptosis goes back to 
the level detected in healthy control subjects29,30. 
The interaction of Fas(CD95/Apo-1) with its ligand 
promotes the deletion of potentially harmful, 
damaged, or unnecessary cells during the immune 
response. This interaction also regulates tissue 
remodeling and homeostasis. Impaired Fas-induced 
apoptosis results in abnormal cell proliferation and 
accumulation, whereas inappropriate expression or 
excessive Fas activity causes tissue damage and Fas 
L system among the most important cell death 
receptors comprising the tumor necrosis factor 
receptor super family, CD95/APO-1(Fas)31,32. 
Our data showed some increase in CD95% 
expression with age but this relation did not reach 
statistical significance (p >0.05). This is supported 
by the results of Schindowski et al.33 who revealed 
that higher susceptibility to apoptosis with aging 
could be due to an enhanced production and 
unsatisfactory elimination of reactive species 
leading to enhanced apoptosis. 
In the present study, the CD95 expression 
decreased with the increase in disease duration. 
Glisic-Milosavljevic34 found that higher level of 
apoptosis was in recent onset DM1 patients and 
apoptosis was similar among both control and long 
standing cases. Also, Allison  et al.28 revealed that 
apoptotic beta cell death was detected in the islets 
of female none obese diabetic (NOD) mice from the 
age of 3 weeks, and the highest level of beta cell 
apoptosis was observed at week 15, which 
coincidence with the earliest onset of diabetes. 
We could not elicit a correlation between CD95 
expression and insulin dose (p > 0.05). Otton et al.10 
reported that insulin therapy reduces the occurrence 
of apoptosis in lymphocytes from diabetic rats as 
compared with untreated cells. This is opposite to 
the data of Glisic-Milosavljevic et al.34 that revealed 
that insulin plays only a minor role in the outcome 
of apoptosis, and the levels of apoptosis are not 
changed greatly by administration of exogenous 
insulin. 
Our study showed a significant correlation 
between CD95 expression and HbA1c (p<0.05). 
Sherif et al. 
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Many studies considered involvement of apoptosis 
in diabetic complications especially nephropathy 
and showed that complicated diabetics usually have 
higher HbA1c reflecting the bad metabolic 
control.36 On the other hand, Tchórzewski et al.1 
reported that there was no correlation between 
glycated hemoglobin level and CD95 percentage 
expression. 
In the present study there was higher CD95 
expression in complicated compared to non 
complicated cases of DM1. Our results were in 
agreement with Baba et al.35 who reported that 
apoptosis is involved in the advancement of 
diabetic nephropathy, and that CD95 expression 
might be a predicting factor for its prognosis. 
In conclusion; the decreased percentage of CD3 
lymphocytes in the peripheral blood  of patients 
with high risk of DM1 is suggestive of the 
involvement of T cells in the local immune 
reactions. Increased peripheral blood T lymphocyte 
percentage with CD95 antigen expression was 
observed in children at high risk of DM1 
(prediabetes) and this event may be critical for the 
early process of diabetogenesis and the mechanism 
responsible for disease progression. Susceptibility 
to apoptosis may be suggested as potential element 
for disease activity assessment. It is recommended 
to estimate CD95% expression on lymphocyte in 
peripheral blood as an additional biomarker of 
autoimmunity in the identification and monitoring 
of DM1 in high risk groups. CD95% could have a 
diagnostic role and may pave the way for the 
possible development of antiapoptotic therapy for 
prevention of DM1. 
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